Table 5.

Median overall survival (OS) and progression-free survival (PFS) for the overall group of patients with SDHx mutation including both subgroups SDHD and SDHB, hormonal status in entry into the study, presence of liver and bone involvement and also clinical response evaluated six weeks after PRRT as partial response (PR), stable disease (SD) or disease progression (PD). Abbreviation: N.R. not reached.

Variable	Subjects	Median OS Months (+/−95% CI)	P-value	Median PFS Months (+/−95% CI)	p-Value
All subjects	13	68.0 (38.6–105.1)		35.0 (24.4–93.1)
Mutation			0.05		0.014
SDHD	8	N.R. (not reached)		N.R. (not reached)
SDHB	5	25.0 (3.2–85.6)		12.0 (2.3–48.8)
Clinical response			0.005		0.0004
PR	8	N.R. (not reached)		N.R. (not reached)
SD/DP	5	22.0 (6.5–27.9)		7.0 (3.8–11.8)
Liver mts			0.033		0.005
present	7	25.0 (6.0–67.7)		10.0 (1.3–39.0)
absent	6	N.R. (not reached)		N.R. (not reached)
Bone mts			0.029		0.0027
present	9	25.0 (14.1–71.9)		12 (6.3–41.0)
absent	4	N.R. (not reached)		N.R. (not reached)
Hormonal status			0.496		0.84
secretor	4	49.0 (0–152.4)		27.0 (0–148.2)
non-secretor	9	97.0 (30.0–120.1)		60.0 (15.9–109.4)